Amarin has had their time line pushed out some . This delay will allow BOM topline to come out before Amarin gets over the final hurdles of a label expansion and approval. The FDA will have also seen all the BOM data before then. Talk about serendipity ! The BOM results may cause quite a stir especially if its RRR numbers are much greater and Amarin’s are thus eclipsed as being best. The intermediate implications and perceptions rightly or wrongly often become reality . Reata could be in a different landscape with their CKD program. All about the data, and its fallout.